(NASDAQ: HRTX) Heron Therapeutics's forecast annual revenue growth rate of 12.72% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.05%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.65%.
Heron Therapeutics's revenue in 2025 is $148,518,000.On average, 3 Wall Street analysts forecast HRTX's revenue for 2025 to be $23,862,477,994, with the lowest HRTX revenue forecast at $23,346,812,911, and the highest HRTX revenue forecast at $24,394,925,077. On average, 2 Wall Street analysts forecast HRTX's revenue for 2026 to be $27,049,532,308, with the lowest HRTX revenue forecast at $26,073,125,051, and the highest HRTX revenue forecast at $28,025,939,566.
In 2027, HRTX is forecast to generate $32,923,232,217 in revenue, with the lowest revenue forecast at $31,916,312,233 and the highest revenue forecast at $33,930,152,202.